NEOG 250117 17.50C (NEOG250117C17500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

NEOG250117C17500

Watchlist

0.05
-0.02-28.57%

15min DelayClose Jan 10 16:00 ET

0.05High0.05Low

Intraday

5D
Daily

News

Neogen Corp (NEOG) Q2 2025 Earnings Call Highlights: Navigating Challenges With Strategic ...
Yahoo FinanceJan 11 02:00 ET
Express News | Neogen Corp -Expects to Record an Impairment Charge of $461.4 Million in Q2 FY25
ReutersJan 10 16:05 ET
Express News | Neogen Corp Files for Non- Timely 10-Q With U.S. SEC
ReutersJan 10 16:04 ET
Sector Update: Health Care Stocks Decline Premarket Friday
MT NewswiresJan 10 09:12 ET
Neogen Shares Are Trading Lower After the Company Issued FY25 Revenue Guidance Below Estimates.
BenzingaJan 10 09:05 ET
Neogen's Preliminary Fiscal Q2 Adjusted Earnings Unchanged, Revenue Increases; Fiscal 2025 Sales Outlook Lowered
MT NewswiresJan 10 07:25 ET

Comments

Stock_Drift

Jan 10 06:15

$Neogen (NEOG.US)$

Stock_Drift

Sep 19, 2024 07:51

$Neogen (NEOG.US)$

Moomoo AI

Feb 23, 2024 04:37

Despite Neogen's profitability and revenue growth, its share price drop is surprising and needs further investigation. The company's future earnings are crucial for shareholders. The recent loss is less severe than the 8% annual loss over the last half decade. Clear growth indications are needed before assuming share price stability.

Neogen (NASDAQ:NEOG) Investors Are Sitting on a Loss of 58% If They Invested Three Years Ago

Moomoo AI

Nov 1, 2023 09:09

The drop in stock price is in line with the decline in Neogen's earnings, which is expected under normal market conditions. The recent insider buying may suggest some confidence in the company's future prospects despite the slump in financial performance.

Neogen (NASDAQ:NEOG) Investors Are Sitting on a Loss of 58% If They Invested Three Years Ago

Analysts Notebook

Jun 16, 2023 07:08

Columns US Top Rating Updates on 6/16: WST, AZO, RES, EVO and MORE

$MorphoSys (MOR.US)$initiated at overweight by Wells Fargo, announced target price at $17.00.
$Guess (GES.US)$initiated at neutral by UBS, announced targe price at $22.00.
$West Pharmaceutical Services (WST.US)$was upgraded by Bank of America Securities from neutral to buy, increased target price from $390.00 to $405.00.
$AutoZone (AZO.US)$was upgraded by UBS from neutral to buy, increased target price from $2800.00 to $2900.00.
$RPC Inc (RES.US)$was downgr...